Back to List View Graph View

Glypican-3 (GPC3)

Glypican-3 (GPC3) is a heparan sulfate proteoglycan tethered to the outer face of the plasma membrane by a glycosylphosphatidylinositol anchor.

Where the papers sit

11 papers from the last 6 months study Glypican-3 (GPC3) directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 1 human data · 9 preclinical · 1 unclassified

Themes 3 themes · 1 new direction

  • GPC3 Theranostics in Liver Cancer

    GPC3-directed treatment and imaging are moving toward more engineered, localized and paired approaches in hepatocellular carcinoma. Fourth-generation CAR-T cells and cytokine optimization target low-antigen-density tumors, while thermosensitive hydrogels improve local delivery. Albumin-binding peptides and paired radiotheranostics extend GPC3 from a therapeutic target to a platform for PET imaging and treatment monitoring. Biodistribution and antitumor efficacy remain central endpoints.

    5 papers · 45.5%

  • GPC3-Targeted Cellular Therapy

    GPC3-directed CAR-T and CAR-NK therapies are being engineered to improve efficacy against hepatocellular carcinoma and other solid tumors. Manufacturing changes, electrostatic surface optimization and local delivery seek to improve cell persistence and tumor access. Enoblituzumab combinations and CAR-T cells secreting anti-EpCAM bispecific engagers address antigen heterogeneity. Dual GPC3–VEGFR degradation offers a complementary strategy beyond cellular therapy.

    4 papers · 36.4%

  • Others — Liver Cancer Vaccines and Detection

    mRNA-loaded lipid nanoparticles are being used to develop neoantigen vaccines for hepatocellular carcinoma, with tumor eradication shown in mice. Alpha-fetoprotein and the tumor microenvironment recur in the cancer-immunology context. A separate nanoplasmonic biosensor work focuses on whole-blood operation rather than vaccination. The cluster therefore links liver-cancer-oriented translational applications without a single clear research direction.

    2 papers · 18.2%

NEW DIRECTION

GPC3 is used as a directly transduced analyte in an instrument-free whole-blood nanoplasmonic biosensor

The SiNP-chitosan nanocomposite biosensor for hepatocellular carcinoma uses anti-GPC3-functionalized gold nanoparticles embedded in hydrogel beads to convert GPC3 binding in unprocessed finger-prick blood into simultaneous colorimetric and LSPR signals, rather than treating GPC3 only as a tumor-localizing imaging target, vaccine antigen, or therapeutic target. This assigns GPC3 a distinct role as the directly measured analyte in an autonomous point-of-care diagnostic platform, enabling plasma separation and quantitative detection without laboratory instruments or sample processing 42233753Jun.

Papers

The 11 papers from the last 6 months that study Glypican-3 (GPC3) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

GPC3 Theranostics in Liver Cancer (5)
  1. Glypican-3-Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714869
  2. Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 6 Jul 2026 PMID 42407326
  3. Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density. Journal of hematology & oncology · 2 Jul 2026 PMID 42387611
  4. Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma. Molecular pharmaceutics · 8 Jun 2026 PMID 42258609
  5. Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
GPC3-Targeted Cellular Therapy (4)
  1. Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777829
  2. Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies. Hepatology communications · 1 Aug 2026 PMID 42538870
  3. CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
  4. GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
Others — Liver Cancer Vaccines and Detection (2)
  1. A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442546
  2. A SiNP-Chitosan Nanocomposite Converts Hydrophobic 3D-Printed Microchannels into Whole-Blood-Operable Nanoplasmonic Biosensors. ACS biomaterials science & engineering · 3 Jun 2026 PMID 42233753

By study type

Human data, design not indexed (1)
  1. Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 6 Jul 2026 PMID 42407326
Preclinical: animal, cell and lab studies (9)
  1. Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777829
  2. Glypican-3-Targeted Paired Radiotheranostics in Orthotopic Liver Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Sept 2026 PMID 42714869
  3. Manufacturing and electrostatic surface optimization of CAR-T cells improve therapeutic efficacy in liver malignancies. Hepatology communications · 1 Aug 2026 PMID 42538870
  4. CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
  5. Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density. Journal of hematology & oncology · 2 Jul 2026 PMID 42387611
  6. GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. Biochemical and biophysical research communications · 30 Jun 2026 PMID 42378857
  7. Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma. Molecular pharmaceutics · 8 Jun 2026 PMID 42258609
  8. Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
  9. A SiNP-Chitosan Nanocomposite Converts Hydrophobic 3D-Printed Microchannels into Whole-Blood-Operable Nanoplasmonic Biosensors. ACS biomaterials science & engineering · 3 Jun 2026 PMID 42233753
Unclassified: not yet indexed with MeSH (1)
  1. A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442546